Celltrion is betting that a new executive order from U.S. President Donald Trump -- promising drug price cuts of up to 80 percent -- could give its U.S. biosimilars portfolio a long-awaited boost.

The Korean company, which sells biosimilars like Vegzelma (bevacizumab), Zymfentra (Remsima SC, infliximab) and Yuflyma (adalimumab) in the U.S., said the move could help reset the competitive dynamics in a market long dominated by high-cost originators and entrenched middlemen.

In a post Monday on his social media platform, Truth Social, Trump said he would sign “one of the most important executive orders in our country’s history,” pledging to reduce prescription drug prices “almost immediately” by as much as 80 percent.

The order revives a “most-favored nation” pricing policy that would tie U.S. prices to the lowest paid globally and allow patients to buy directly from manufacturers. Companies would have 30 days to comply.

Celltrion, in a statement issued Tuesday in response to shareholder inquiries following Trump’s announcement, said the policy is expected to “create a more favorable business environment,” particularly by undercutting the dominance of pharmacy benefit managers (PBMs) and streamlining access to biosimilars.

“The distribution dominance established by high-margin pharmaceutical companies relying on branded products is expected to weaken,” the company said. “This could create opportunities for biosimilar companies operating in a competitive landscape to expand their market presence.”

Celltrion said that under the current U.S. reimbursement structure, branded drugs are typically listed first in formularies, while biosimilars face limited inclusion and are often priced at levels similar to originators due to PBM rebate arrangements.

“With improvements in the intermediary distribution structure, the actual prescription prices of biosimilars will be reduced,” the company said. “This will accelerate the expansion of biosimilar prescriptions to levels similar to those in Europe.”

The company also said that if the order allows for parallel imports, it may be able to introduce products in the U.S. that it has not yet launched. With a direct sales network already in place, the company said it can “accelerate sales by expanding our product portfolio and leveraging marketing synergies,” based on its commercial experience in Europe.

“We believe that [the executive order] will work in favor of biosimilar manufacturers,” the company said. “For companies like Celltrion, which directly sells biosimilars in the U.S., it presents another significant opportunity.”

In a separate update last Friday, the company also addressed growing speculation that the Trump administration may impose pharmaceutical-specific tariffs, saying it had already transferred 15 months’ worth of inventory for U.S. sale this year and secured local contract manufacturing to hedge against potential disruptions.

Celltrion added that it is conducting a feasibility study for its first U.S.-based API facility, calling the move part of a “more fundamental, long-term solution.”